原著論文

1. Yoshimura A, Okubo T, Kiguchi T, Jenkins NA T, Gilbert DJ, Copeland NG, Hara T, Miyajima A. A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin recepters. EMBO Journal 14(12)：2816-26  1995    
2. Miyazono T, Niiya K, Kiguchi T, Shibakura M, Takahara T, Harada M , Watanabe A. Oxidative stress induces urokinase-type plasminogen activator in RC-K8 human maliganant lymphoma cells and H69 human small cell lung carcinoma cells. Fibrinolysis & Proteolysis 14: 366-373  2000 
3. Kiguchi T, Niiya K, Shibakura M, Miyazono T, Shinagawa K, Ishimaru F, Kiura K, Ikeda K, Nakata Y, Harada M. Induction of urokinase-type plasminogen activator by the anthracycline antibiotic in human RC-K8 lymphoma and H69 lung carcinoma cells. Int J Cancer. 93(6):792-797, 2001
4. Niiya K, Kiguchi T, Dansako H, Fujimura K, Fujimoto T, Iijima K, Tanimoto M, Harada M. Two novel gene mutations in type I antithrombin deficiency. Int J Hematol. 74(4):469-72 2001 
5. Shibakura M, Niiya K, Kiguchi T, Nakata Y, Tanimoto M. Camptothecin induces urokinase-type plasminogen activator gene-expression in human RC-K8 malignant lymphoma and H69 small cell lung cancer cells. Acta Med Okayama. 56(5):223-7 2002  
6. Shibakura M, Niiya K, Kiguchi T, Shinagawa K, Ishimaru F, Ikeda K, Namba M, Nakata Y, Harada M, Tanimoto M. Simultaneous induction of matrix metalloproteinase-9 and interleukin 8 by all-trans retinoic acid in human PL-21 and NB4 myeloid leukaemia cells. Br J Haematol. 118(2):419-25 2002 
7. Shibakura M, Niiya K, Kiguchi T, Kitajima I, Niiya M, Asaumi N, Huh NH, Nakata Y, Harada M, Tanimoto M. Induction of IL-8 and monoclyte chemoattractant protein-1 by doxorubicin in human small cell lung carcinoma cells. Int J Cancer. 103(3):380-6 2003  
8. Niiya M, Niiya K, Kiguchi T, Shibakura M, Asaumi N, Shinagawa K, Ishimaru F, Kiura K, Ikeda K, Ueoka H, Tanimoto M. Induction of TNF-alpha, uPA, IL-8 and MCP-1 by doxorubicin in human lung carcinoma cells. Cancer Chemother Pharmacol. 52(5):391-8 2003 
9. Ito Y, Ohyashiki K, Yoshida I, Takeuchi M, Aoyama Y, Mugitani A, Matsuura Y, Wakita H, Matsuda M, Sakamoto E, Kiguchi T, Urabe A, Tamura K, Kanamaru A, Masaoka T. The prophylactic effect of itraconazole capsules and flconazol capsules for systemic fungul infections in patients with acute myeloid leukemia and myelodysplastic symdrome: A Japanese multicenter randomized, controlled study. Int J Hematol. 85(2): 121-127 2007 
10. Ohyashiki K, Kiguchi T, Ito Y, Gotoh A, Tauchi T, Miyazawa K, Kimura Y, Hisatomi H, Ohyashiki JH. Isolated erythrocythemia: a distinct entity or a sub-type of polycythemia vera?. Jpn J Clin Oncol. 38(3):230-232 2008.
11. Ohyashiki K, Kiguchi T, Ito Y, Fujimoto H, Gotoh A, Tauchi T, Miyazawa K, Kimura Y, Ohyashiki JH. Leukocytosis is linked to thrombosis at diagnosis, while JAK2 V617F mutation is associated with thrombosis during the course of essential thrombocythemia. Int J Hematol. 2008 ;87(4):446-8. 
12. Kiguchi T, Tauchi T, Ito Y, Miyazawa K, Kimura Y, Ohyashiki K.: Compliance with taking imatinib mesylate in patients with chronic myeloid leukemia in the chronic phase. Leuk Res. 2009 ;33(3):506-8.  
13. Kiguchi T, Ito Y, Kimura Y, Ohyashiki K. Restoration of cardiac function by an iron chelator, deferasirox, in a patient with aplastic anemia and cardiac iron overload. Int J Hematol. 2009 ;89(4):546-8.  
14. Nishimori H, Matsuo K, Maeda Y, Nawa Y, Sunami K, Togitani K, Takimoto H, Hiramatsu Y, Kiguchi T, Yano T, Yamane H, Tabayashi T, Takeuchi M, Makita M, Sezaki N, Yamasuji Y, Sugiyama H, Tabuchi T, Kataoka I, Fujii N, Ishimaru F, Shinagawa K, Ikeda K, Hara M, Yoshino T, Tanimoto M; West-Japan Hematology and Oncology Group. The effect of adding rituximab to CHOP-based therapy on clinical outcomes for Japanese patients with diffuse large B-cell lymphoma: a propensity score matching analysis. Int J Hematol. 2009 ;89(3):326-31. 
15. Kiguchi T, Yoshino Y, Yuan B, Yoshizawa S, Kitahara T, Akahane D, Gotoh M, Kaise T, Toyoda H, Ohyashiki K. Speciation of arsenic trioxide penetrates into cerebrospinal fluid in patients with acute promyelocytic leukemia. Leuk Res.;34(3):403-5, 2010 
16. Kihara R, Nagata Y, Kiyoi H, Kato T, Yamamoto E, Suzuki K, Chen F, Asou N, Ohtake S, Miyawaki S, Miyazaki Y, Sakura T, Ozawa Y, Usui N, Kanamori H, Kiguchi T, Imai K, Uike N, Kimura F, Kitamura K, Nakaseko C, Onizuka M, Takeshita A, Ishida F, Suzushima H, Kato Y, Miwa H, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Ogawa S, Naoe T. Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients. Leukemia. 2014 ; 28(8):1586-95.
17. Tamura K, Kawai Y, Kiguchi T, Okamoto M, Kaneko M, Maemondo M, Gemba K, Fujimaki K, Kirito K, Goto T, Fujisaki T, Takeda K, Nakajima A, Ueda T. Efficacy and safety of febuxostat for prevention of tumor lysis syndrome in patients with malignant tumors receiving chemotherapy: a phase III, randomized, multi-center trial comparing febuxostat and allopurinol. Int J Clin Oncol. 2016 Oct;21(5):996-1003. 
18. Katsuyama T, Sada KE, Yan M, Zeggar S, Hiramatsu S, Miyawaki Y, Ohashi K, Morishita M, Watanabe H, Katsuyama E, Takano-Narazaki M, Toyota-Tatebe N, Sunahori-Watanabe K, Kawabata T, Miyake K, Kiguchi T, Wada J. Prognostic factors of methotrexate-associated lymphoproliferative disorders associated with rheumatoid arthritis and plausible application of biological agents. Mod Rheumatol. 2017 Sep;27(5):773-777.  
19. Ogawa Y, Izutsu K, Kiguchi T, Choi I, Takatsuka Y, Ando K, Suzumiya J; Japanese Bendamustine CLL Study Group. A multicenter, single-arm, Phase II clinical trial of bendamustine monotherapy in patients with chronic lymphocytic leukemia in Japan. Int J Hematol. 2017 May;105(5):631-637. 
20. Maruyama D, Tobinai K, Ogura M, Uchida T, Hatake K, Taniwaki M, Ando K, Tsukasaki K, Ishida T, Kobayashi N, Ishizawa K, Tatsumi Y, Kato K, Kiguchi T, Ikezoe T, Laille E, Ro T, Tamakoshi H, Sakurai S, Ohtsu T. Romidepsin in Japanese patients with relapsed or refractory peripheral T-cell lymphoma: a phase I/II and pharmacokinetics study. Int J Hematol. 2017 Nov;106(5):655-665. 
21. Takahashi N, Tauchi T, Kitamura K, Miyamura K, Saburi Y, Hatta Y, Miyata Y, Kobayashi S, Usuki K, Matsumura I, Minami Y, Usui N, Fukuda T, Takada S, Ishikawa M, Fujimaki K, Gomyo H, Sasaki O, Ohishi K, Miyake T, Imai K, Suzushima H, Mitsui H, Togitani K, Kiguchi T, Atsuta Y, Ohtake S, Ohnishi K, Kobayashi Y, Kiyoi H, Miyazaki Y, Naoe T; Japan Adult Leukemia Study Group. Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study. Int J Hematol. 2018 107(2):185-193.  
22. Sadatani K, Niiya K, Sonobe H, Sasaki K, Miyamoto I, Nakano M, Habara T, Kiguchi T. Prolonged Activated Partial Thromboplastin Time and False-Positive Results for Fibrinogen and Fibrin Degradation Products in a B-Cell Lymphoma Patient. Ann Clin Lab Sci. 2018 May;48(3):377-380.
23. Matsue K, Kumagai K, Sugiura I, Ishikawa T, Igarashi T, Sato T, Uchiyama M, Miyamoto T, Ono T, Ueda Y, Kiguchi T, Sunaga Y, Sasaki T, Suzuki K. Plerixafor for mobilization and collection of haematopoietic stem cells for autologous transplantation in Japanese patients with non-Hodgkin lymphoma: a randomized phase 2 study. Int J Hematol. 2018 108(5):524-534.
24. Murakami H, Kasamatsu T, Murakami J, Kiguchi T, Kanematsu T, Ogawa D, Takamatsu H, Handa H, Ozaki S, Miki H, Takahashi T, Takeo T, Yamauchi T, Morishita T, Kosugi H, Shimizu K. Thalidomide maintenance therapy in Japanese myeloma patients: a multicenter, phase II clinical trial (COMET study). Int J Hematol. 2019 110(1):125-126.
25. Sunami K, Matsumoto M, Fuchida SI, Omoto E, Takamatsu H, Adachi Y, Choi I, Fujishima N, Kiguchi T, Miyamoto T, Maeda A, Suzumiya J, Yamamura R, Nagafuji K, Nakazato T, Kuroda Y, Yujiri T, Takamatsu Y, Harada M, Akashi K. Bortezomib-based strategy with autologous stem cell transplantation for newly diagnosed multiple myeloma: a phase II study by the Japan Study Group for Cell Therapy and Transplantation (JSCT-MM12). Int J Clin Oncol. 2019 Aug;24(8):966-975. 
26. Ishikawa Y, Kawashima N, Atsuta Y, Sugiura I, Sawa M, Dobashi N, Yokoyama H, Doki N, Tomita A, Kiguchi T, Koh S, Kanamori H, Iriyama N, Kohno A, Moriuchi Y, Asada N, Hirano D, Togitani K, Sakura T, Hagihara M, Tomikawa T, Yokoyama Y, Asou N, Ohtake S, Matsumura I, Miyazaki Y, Naoe T, Kiyoi H. Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11. Blood Adv. 2020 Jan 14;4(1):66-75. 
27. Izutsu K, Minami Y, Fukuhara N, Terui Y, Jo T, Yamamoto G, Ishikawa T, Kobayashi T, Kiguchi T, Nagai H, Ohtsu T, Kalambakas S, Fustier P, Midorikawa S, Tobinai K. Analysis of Japanese Patients From the AUGMENT Phase III Study of Lenalidomide + Rituximab (R 2) vs. Rituximab + Placebo in relapsed/refractory Indolent non-Hodgkin Lymphoma. Int J Hematol. 2020 Mar;111(3):409-416.
28. Ishida T, Kimura H, Ozaki S, Kubo K, Sunami K, Takezako N, Fujita H, Hayashi T, Kiguchi T, Ohashi K, Yamamoto S, Takamatsu H, Kosugi H, Ohta K, Sakai R, Handa H, Kondo S, Abe Y, Omoto E, Mitani K, Morita S, Murakami H, Shimizu K. Continuous lenalidomide treatment after bortezomib-melphalan-prednisolone therapy for newly diagnosed multiple myeloma. Ann Hematol. 2020 May;99(5):1063-1072. 
29. Bernard E, Nannya Y, Hasserjian RP, Devlin SM, Tuechler H, Medina-Martinez JS, Yoshizato T, Shiozawa Y, Saiki R, Malcovati L, Levine MF, Arango JE, Zhou Y, Solé F, Cargo CA, Haase D, Creignou M, Germing U, Zhang Y, Gundem G, Sarian A, van de Loosdrecht AA, Jädersten M, Tobiasson M, Kosmider O, Follo MY, Thol F, Pinheiro RF, Santini V, Kotsianidis I, Boultwood J, Santos FPS, Schanz J, Kasahara S, Ishikawa T, Tsurumi H, Takaori-Kondo A, Kiguchi T, Polprasert C, Bennett JM, Klimek VM, Savona MR, Belickova M, Ganster C, Palomo L, Sanz G, Ades L, Della Porta MG, Smith AG, Werner Y, Patel M, Viale A, Vanness K, Neuberg DS, Stevenson KE, Menghrajani K, Bolton KL, Fenaux P, Pellagatti A, Platzbecker U, Heuser M, Valent P, Chiba S, Miyazaki Y, Finelli C, Voso MT, Shih LY, Fontenay M, Jansen JH, Cervera J, Atsuta Y, Gattermann N, Ebert BL, Bejar R, Greenberg PL, Cazzola M, Hellström-Lindberg E, Ogawa S, Papaemmanuil E. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nat Med. 2020 Oct;26(10):1549-1556.
30. Sunami K, Suzuki K, Ri M, Matsumoto M, Shimazaki C, Asaoku H, Shibayama H, Ishizawa K, Takamatsu H, Ikeda T, Maruyama D, Kaneko H, Uchiyama M, Kiguchi T, Iyama S, Murakami H, Takahashi K, Tada K, Macé S, Guillemin-Paveau H, Iida S. Isatuximab monotherapy in relapsed/refractory multiple myeloma: A Japanese, multicenter, phase 1/2, safety and efficacy study. Cancer Sci. 2020 Dec;111(12):4526-4539.
31. Chen S, Kiguchi T, Nagata Y, Tamai Y, Ikeda T, Kajiya R, Ono T, Sugiyama D, Nishikawa H, Akatsuka Y. A simple method to distinguish residual elotuzumab from monoclonal paraprotein in immunofixation assays for multiple myeloma patients. Int J Hematol. 2021 Apr;113(4):473-479. doi: 10.1007/s12185-021-03088-9.
32. Miyamoto T, Iino M, Komorizono Y, Kiguchi T, Furukawa N, Otsuka M, Sawada S, Okamoto Y, Yamauchi K, Muto T, Fujisaki T, Tsurumi H, Nakamura K. Screening for Gaucher Disease Using Dried Blood Spot Tests: A Japanese Multicenter, Cross-sectional Survey. Intern Med. 2021;60(5):699-707. doi: 10.2169/internalmedicine.5064-20.
33. Murai K, Ureshino H, Kumagai T, Tanaka H, Nishiwaki K, Wakita S, Inokuchi K, Fukushima T, Yoshida C, Uoshima N, Kiguchi T, Mita M, Aoki J, Kimura S, Karimata K, Usuki K, Shimono J, Chinen Y, Kuroda J, Matsuda Y, Nakao K, Ono T, Fujimaki K, Shibayama H, Mizumoto C, Takeoka T, Io K, Kondo T, Miura M, Minami Y, Ikezoe T, Imagawa J, Takamori A, Kawaguchi A, Sakamoto J, Kimura S. Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2021 Dec;8(12):e902-e911. doi: 10.1016/S2352-3026(21)00333-1.
34. Murayama K, Kiguchi T, Izutsu K, Kameoka Y, Hidaka M, Kato H, Rai S, Kuroda J, Ishizawa K, Ichikawa S, Ando K, Ogura M, Fukushima K, Terui Y. Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma. Ann Hematol. 2022 May;101(5):979-989. doi: 10.1007/s00277-022-04801-2.
35. Ikezoe T, Ando K, Onozawa M, Yamane T, Hosono N, Morita Y, Kiguchi T, Iwasaki H, Miyamoto T, Matsubara K, Sugimoto S, Miyazaki Y, Kizaki M, Akashi K. Phase I study of alvocidib plus cytarabine/mitoxantrone or cytarabine/daunorubicin for acute myeloid leukemia in Japan. Cancer Sci. 2022 Jun 11. doi: 10.1111/cas.15458.
36. Iida H, Imada K, Ueda Y, Kubo K, Yokota A, Ito Y, Kiguchi T, Hata T, Nawa Y, Ikezoe T, Uchida T, Morita Y, Kawashima I, Chiba M, Morimoto K, Hirooka S, Miyazaki Y, Ohno R, Naoe T; Study Group. A phase II randomized study evaluating azacitidine versus conventional care regimens in newly diagnosed elderly Japanese patients with unfavorable acute myeloid leukemia. Int J Hematol. 2022 May;115(5):694-703. doi: 10.1007/s12185-022-03307-x.
37. Miyazaki Y, Kiguchi T, Sato S, Usuki K, Ishiyama K, Ito Y, Suzuki T, Taguchi J, Chiba S, Dobashi N, Tomita A, Harada H, Handa H, Horiike S, Maeda T, Matsuda M, Ichikawa M, Hata T, Honda S, Iyama S, Suzushima H, Moriuchi Y, Kurokawa T, Yokota K, Ohtake S, Yamauchi T, Matsumura I, Kiyoi H, Naoe T; Japan Adult Leukemia Study Group. Prospective comparison of 5- and 7-day administration of azacitidine for myelodysplastic syndromes: a JALSG MDS212 trial. Int J Hematol. 2022 Aug;116(2):228-238. doi: 10.1007/s12185-022-03347-3.
38. Kiguchi T, Yamaguchi M, Takezako N, Miyawaki S, Masui K, Ihara Y, Hirota M, Shimofurutani N, Naoe T. Efficacy and safety of Wilms’ tumor 1 helper peptide OCV-501 in elderly patients with acute myeloid leukemia: a multicenter, randomized, double-blind, placebo-controlled phase 2 trial. Cancer Immunol Immunother. 2022 Jun;71(6):1419-1430. doi: 10.1007/s00262-021-03074-4.
39. Sekiguchi N, Kasahara S, Miyamoto T, Kiguchi T, Ohno H, Takagi T, Tachibana M, Sumi H, Kakurai Y, Yamashita T, Usuki K. Phase I dose-escalation study of milademetan in patients with relapsed or refractory acute myeloid leukemia. Int J Hematol. 2023 Jan;117(1):68-77.
40. Makishima H, Saiki R, Nannya Y, Korotev SC, Gurnari C, Takeda J, Momozawa Y, Best S, Krishnamurthy P, Yoshizato T, Atsuta Y, Shiozawa Y, Iijima-Yamashita Y, Yoshida K, Shiraishi Y, Nagata Y, Kakiuchi N, Onizuka M, Chiba K, Tanaka H, Kon A, Ochi Y, Nakagawa MM, Okuda R, Mori T, Yoda A, Itonaga H, Miyazaki Y, Sanada M, Ishikawa T, Chiba S, Tsurumi H, Kasahara S, Müller-Tidow C, Takaori-Kondo A, Ohyashiki K, Kiguchi T, Matsuda F, Jansen JH, Polprasert C, Blombery P, Kamatani Y, Miyano S, Malcovati L, Haferlach T, Kubo M, Cazzola M, Kulasekararaj AG, Godley LA, Maciejewski JP, Ogawa S. Germline DDX41 mutations define a unique subtype of myeloid neoplasms. Blood. 2023 Feb 2;141(5):534-549. doi: 10.1182/blood.2022018221.
41. Nannya Y, Tobiasson M, Sato S, Bernard E, Ohtake S, Takeda J, Creignou M, Zhao L, Kusakabe M, Shibata Y, Nakamura N, Watanabe M, Hiramoto N, Shiozawa Y, Shiraishi Y, Tanaka H, Yoshida K, Kakiuchi N, Makishima H, Nakagawa M, Usuki K, Watanabe M, Imada K, Handa H, Taguchi M, Kiguchi T, Ohyashiki K, Ishikawa T, Takaori-Kondo A, Tsurumi H, Kasahara S, Chiba S, Naoe T, Miyano S, Papaemanuil E, Miyazaki Y, Hellström-Lindberg E, Ogawa S. Postazacitidine clone size predicts long-term outcome of patients with myelodysplastic syndromes and related myeloid neoplasms. Blood Adv. 2023 Jul 25;7(14):3624-3636. doi: 10.1182/bloodadvances.2022009564.
42. Sunami K, Fuchida SI, Suzuki K, Ri M, Matsumoto M, Shimazaki C, Asaoku H, Shibayama H, Ishizawa K, Takamatsu H, Ikeda T, Maruyama D, Imada K, Uchiyama M, Kiguchi T, Iyama S, Murakami H, Onishi R, Tada K, Iida S. Anti-CD38 antibody isatuximab monotherapy for Japanese individuals with relapsed/refractory multiple myeloma: An update of the phase 1/2 ISLANDs study. Hematol Oncol. 2023 Aug;41(3):442-452. doi: 10.1002/hon.3105.
43. Kiguchi T, Sakurai M, Tanaka Y, Kuramoto K, Kado Y, Sawada S, Mitomi T. A real-world, retrospective, observational study examining treatment patterns and clinical outcomes in patients with FLT3m + AML in Japan. Curr Med Res Opin. 2023 Oct 26:1-10. doi: 10.1080/03007995.2023.2271390.

症例報告

1. Kiguchi T, Kimura F, Niiya K, Katayama Y, Harada M. Acute thrombocytopenic purpura after ingesting of Sho-saiko-to preparation for hepatitis. Liver 20(6): 491  2000  
2. Yamamoto K, Niiya K, Shigematu T, Kiguchi T, Takenaka K, Shinagawa K, Ishimaru F, Ikeda K, Shima M, Harada M. Transient factor VIII inhibitor in a hemophilia patient after staphylococcal septic shock syndrome. Int. J. hematol 2000 72(4): 517-19  
3. Kiguchi T, Niiya K, Yamawaki Y, Shima M, Harada M. Development of factor VIII inhibitor in three non-hemophiliac patients. Rinsho Ketsueki. 41(11):1195-1200, 2000
4. Emori Y, Sakugawa M, Niiya K, Kiguchi T, Kojima K, Takenaka K, Shinagawa K, Ishimaru F, Ikeda K, Tanimoto M, Yamasaki R, Ohara N, Harada M. Life-threatening bleeding and acquired factor V deficiency associated with primary systemic amyloidosis. Blood Coagul Fibrinolysis. 13(6):555-9 2002
5. Asaumi N, Masuda K, Yoshida C, Kiguchi T, Niiya M, Niiya K, Tanimoto M. Helicobacter pylori eradication based upon a drug sensitivity test effectively increased platelet count in a patient with refractory idiopathic thrombocytopenic purpura. Rinsho Ketsueki. 44(7):480-2 2003
6. Fujii M, Tanimoto Y, Kiguchi T, Takehara H, Fujimori Y, Teshima T, Kanehiro A, Shinagawa K, Tada S, Kataoka M, Tanimoto M: Pulmonary infiltration with eosinophilia syndrome complicated with non-Hodgkin’s lymphoma of B cell lineage. Allergology International 52: 161-164, 2003 
7. Nishiuchi T, Imachi H, Fujiwara M, Murao K, Onishi H, Kiguchi T, Takimoto H, Kushida Y, Haba R, Ishida T. A case of non-Hodgkin’s lymphoma primary arising in both adrenal glands associated with adrenal failure. Endocrine. 2009 ;35(1):34-7.  
8. Yoshizawa S, Gotoh M, Kitahara T, Kiguchi T, Akahane D, Sakuta J, Sunaga K, Ohyashiki K. Micafungin-induced hemolysis attack due to drug-dependent antibody persisting for more than 6 weeks. Leuk Res. 2010 ;34(2):e60-1.
9. Gotoh M, Tauchi T, Yoshizawa S, Kitahara T, Kiguchi T, Kimura Y, Ohyashiki K. Successful prior treatment with dasatinib followed by stem cell transplantation in a patient with CML in blastic crisis with a BCR-ABL mutation. Int J Hematol. ;91(1):128-31, 2010 
10. Kiguchi T, Tauchi T, Ohyashiki K. Molecular relapse of chronic myeloid leukemia after discontinuation of imatinib mesylate for maintaining complete molecular response for more than 2 years. Rinsho Ketsueki. 2009 ;50(1):52-4. 
11. Yoshizawa S, Akahane D, Fujimoto H, Gotoh M, Kiguchi T, Tauchi T, Ohyashiki K. Effective and well tolerated treatment with melphalan and dexamethasone for primary systemic AL amyloidosis with cardiac involvement. Rinsho Ketsueki. 2009 ;50(11):1647-51.
12. Ninomiya K, Mannami T, Seno S, Suzuki Y, Tamura T, Kimura K, Kubo T, Masunari T, Okada T, Kiguchi T, Sezaki N, Harita S, Nakata Y, Sonobe H. A case of advanced gastric cancer with multiple bone metastases and disseminated intravascular coagulation successfully treated by combination chemotherapy of S-1 plus docetaxel. Gan To Kagaku Ryoho. 2012 ;39(11):1719-22.
13. Kimura Y, Gotoh A, Katagiri S, Hoshi Y, Uchida S, Yamasaki A, Takahashi Y, Fukutake K, Kiguchi T, Ohyashiki K. Transfusion-transmitted hepatitis E in a patient with myelodysplastic syndromes. Blood Transfus. 2014 Jan;12(1):103-6.
14. Meguri Y, Kambara Y, Yamamoto A, Masunari T, Sezaki N, Kiguchi T. Development of unexpected severe thrombocytopenia just after initiating lenalidomide: possible involvement of an immunologic mechanism. Int J Myeloma 8(1): 1–3, 2018
15. Kiguchi T. State-of-the-art treatment of acute promyelocytic leukemia. Rinsho Ketsueki. 2018 59(10):2007-2018.
16. Yamamoto A, Meguri Y, Fukuda A, Kambara Y, Urata T, Kuroi T, Masunari T, Sezaki N, Kiguchi T. A case of reversible cerebral vasoconstriction syndrome developing during treatment of adult aplastic anemia. Ann Hematol. 2019; 98(2):511-513.
17. Meguri Y, Asada N, Nakasako Y, Kondo E, Kambara Y, Yamamoto A, Masunari T, Sezaki N, Ikeda G, Toji T, Yoshino T, Kiguchi T. A case report of TAFRO syndrome successfully treated by immunosuppressive therapies with plasma exchange. Ann Hematol. 2019;98(2):537-539. 
18. Kiguchi T. Maintenance therapy for acute myeloid leukemia (including in patients who have undergone transplantation) including off-label use drugs in Japan. Rinsho Ketsueki. 2021 62(8):978-987.
19. Kiso S, Sugiura H, Kuroi T, Omote R, Toji T, Ishikawa T, Okamoto S, Nomura N, Masunari T, Sezaki N, Kiguchi T, Tanimoto M. Concurrent Onset of Chronic Lymphocytic Leukemia and Atypical Phenotype Acute Myeloid Leukemia Revealed by Autopsy. Case Rep Oncol. 2021 Nov 30;14(3):1725-1732. doi: 10.1159/000520427.
20. Sugiura H, Sezaki N, Ishikawa T, Kuroi T, Okamoto S, Nomura N, Masunari T, Nakasako Y, Kiguchi T, Tanimoto M. Successful treatment of relapsed chronic lymphocytic leukemia with venetoclax in a patient with severe chronic kidney disease. Clin Case Rep. 2022 Apr 14;10(4):e05735. doi: 10.1002/ccr3.5735.
21. 木口　亨、各務慎一、他：B細胞性前リンパ球性白血病の1例。香川労災病院雑誌 12: 61-64, 2006
22. 木口　亨、滝本秀隆：Cytarabine ocfosfate経口投与で長期に亘って寛解を維持しえた難治性急性骨髄性白血病。香川労災病院雑誌 12: 65-68, 2006
23. 佐藤恭子、寺西幸司、三好久昭、木口　亨、他：胃のT細胞性悪性リンパ腫として発見され急速に中枢神経症状を来した1例。香川県内科医師会誌　第42巻: 73-77, 2006
24.  鈴木裕史、定平　健、安原ひさ恵、田村敬博、多田譲治、吉野　正、市村浩一、木口　亨他、皮疹で発症したNK/T-cell lymphomaの1例。香川県立中央病院医学雑誌　第25巻: 25-29, 2006
25.  藤原真子、井町仁美、村尾考児、大西宏明、石田俊彦、北村悠希、木口　亨、滝本秀隆、串田吉生、羽場礼次：副腎不全で発見された非ホジキンリンパ腫の１症例。日本内科学会雑誌　第96巻：134-136, 2007 

 

医学研究

労働省（現厚生労働省）

労働福祉事業団　医学研究　第3種研究区分

血栓症の発症要因-脳梗塞、心筋梗塞を中心にして-

主任研究者　岡山労災病院　内科　木口　亨

研究期間　2002年4月～2005年3月

2003年　50万円

2004年　25万円

 

　AMED

研究開発課題名：PDX治療モデルを併用した治療抵抗性急性骨髄性白血病クローンの成立過程に生じる分子病態に基づく層別化システムの確立と標準治療薬開発に関する研究

研究開発責任者：名古屋大学　血液・腫瘍内科学　教授　清井　仁　

研究開発分担者：獨協医科大学埼玉医療センター　糖尿病内分泌・血液内科　准教授　木口　亨

研究機関　2020年4月1日～2023年3月31日

 

　AMED

研究開発課題名：本邦における初発急性前骨髄球性白血病に対するATRA・ATO併用分化誘導療法の確立

研究開発責任者：筑波大学　血液内科　講師　横山泰久　

研究開発分担者：獨協医科大学埼玉医療センター　糖尿病内分泌・血液内科　准教授　木口　亨

研究機関　2021年10月1日～2024年3月31日

 

AMED

研究開発課題名：PDX治療モデルと継時的臨床検体の統合的マルチオミックス解析に基づく急性骨髄性白血病の分子層別化と難治性クローンの克服に向けた治療戦略の構築に関する研究

研究開発責任者：名古屋大学　血液・腫瘍内科学　教授　清井　仁

研究開発分担者：獨協医科大学埼玉医療センター　糖尿病内分泌・血液内科　准教授　木口　亨

研究機関　2023年4月1日～2026年3月31日

 

政策提言

・造血細胞移植ガイドライン 急性骨髄性白血病（日本造血細胞移植学会編　2019年）

・日本血液学会　造血器腫瘍診療ガイドライン第3版(APL担当)

 

著書

1. 医学スーパーラーニングシリーズ 血液内科学　丸善出版 2011年　分担執筆
2. 白血病診療Q & A　一つ上を行く診療の実践　中外医学社 2015年　分担執筆
3. 私の治療　急性前骨髄球性白血病　「日本医事新報」 No.4971　2019年
4. 急性前骨髄球性白血病　「内科」第124巻第4号　南江堂　2019年
5. 高齢者骨髄異形成症候群の治療方針と注意点　「血液内科」　科学評論社，Vol.81-No.2，2020年
6. 目前に控える新たな急性骨髄性白血病治療　「ヘマトロジー2」 クリニコ出版　2020年　分担執筆
7. 急性前骨髄球性白血病に対する治療　「日本臨床」　78巻3号2020年　分担執筆
8. 急性前骨髄球性白血病　「造血器腫瘍学　第2版」　日本臨床，2020年　分担執筆
9. APLの治療（地固め療法）「急性白血病診療テキスト」中外医学社　2020年　分担執筆
10. 急性前骨髄球性白血病　C再発・難治例の治療プロトコール「白血病治療マニュアル　改訂第4版」　南江堂　2020年　分担執筆
11. 急性前骨髄球性白血病(APL)の治療と今後、問題点について　「日本医事新報」 No.5032　2020年
12. 骨髄異形成症候群に対するazacitidine療法の至適化　「血液内科」　科学評論社，Vol.82-No.6，2021年
13. APLに対する分子標的治療　週間医学のあゆみ　Vol278, No.13, p1102-1106, 2021
14. 急性前骨髄球性白血病　「専門医のための血液病学」　医学書院　p134-140, 2022　分担執筆
15. 血液疾患　最新の治療2023-2025　南江堂　p115-117, 2022 分担執筆
16. ASH2022 meeting report  2)急性白血病　「腫瘍内科」科学評論社, 第31巻第4号, p485-491, 2023年

 

総説

骨髄増殖性疾患—今，最も注目される血液疾患の最前線　　

骨髄増殖性疾患の病態・診断・治療　　慢性好酸球性白血病の分子病態と治療　

木口亨、大屋敷一馬　カレントテラピー巻:２６ 号:６ 頁:513-516 2008年

 

Akihiro Takeshita, Katsuji Shinagawa, Miwa Adachia, Takaaki Onoa, Toru Kiguchi, Tomoki Naoe. Tamibarotene for the treatment of acute promyelocytic leukemia. Expert Opinion on Orphan Drugs. 2014 ; 2 : 961-969.

 

特集　急性骨髄性白血病(AML) -新分類・分子病態・治療-

5. 急性前骨髄球性白血病(APL)の治療選択

木口　亨、廻　勇輔　血液フロンティア　Vol.27 No.4 2017  p53-61

 

「臨床血液」教育講演特集号　

APL治療の最前線　 臨床血液 59巻10号（2018年）p147-158　 

AMLの維持療法（移植後も含めて） —日本での保険適用外医薬品を含む—　 臨床血液 62巻8号（2021年）p978-982　

 

受賞歴

Plenary oral session

第42回日本臨床血液学会総会

３例のI型アンチトロンビン欠損症の遺伝子解析

木口　亨、新谷憲治、藤村欣吾、藤元貴啓、飯島憲司、原田実根

2000. 11. 10（倉敷市民会館）